April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in a U.S. trial. Data from the RESOLUTE U.S. trial was presented this week at the American College of Cardiology (ACC) Scientific Session in New Orleans.

The RIVAL Trial showed radial access has advantages to femoral access.

April 8, 2011 — In the largest randomized trial to compare radial access and femoral access for coronary angiography and intervention, researchers found radial access reduced rates of vascular complications, according to research presented this week at the American College of Cardiology (ACC) Scientific Session in New Orleans.

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led to a lower combined rate of death, heart attack and repeat revascularization. The research findings were presented this week at the American College of Cardiology’s 60th Annual Scientific Session.

April 8, 2011 – A Canadian research team found that the radial artery outperformed the saphenous vein as the best conduit for coronary artery bypass graft (CABG) surgery. The radial artery also led to reduced rates of functional or complete graft occlusion, according to research presented this week at the American College of Cardiology’s 60th Annual Scientific Session.

The transcatheter MitraClip mitral valve repair system continues to compare favorably with conventional open-heart surgery for treatment of select patients with mitral regurgitation. The findings come from updated research from the EVEREST II study presented at the American College of Cardiology’s 60th Annual Scientific Session.

April 8, 2011 — A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to coronary artery bypass surgery (CABG) in patients with unprotected left main coronary artery disease.

To prevent physician fatigue and back pain associated with wearing protective lead aprons in the cath lab, the ZeroGravity Radiation Protection System offers increased radiation protection without weighing down the user. Using a ceiling suspended gantry system, no weight is placed on the body of the interventionalist and it allows for smooth movement along the X, Y, Z axis.


April 8, 2011 – The U.S. Food and Drug Administration (FDA) has approved an aneurysm treatment system as a Humanitarian Use Device (HDE). NeuroVasx’s cPAX Aneurysm Treatment System can be used to treat large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat.

The HDE allows for the treatment of up to 4,000 patients per year in the United States.
Heavy calcification around the Aortic bifurcation in a 3,000 year old mummy.
CT scan of an Egyptian mummy.
Heavy calcification of the aortic valve annulus in a 3,000 year old Egyptian mummy.
Heavy calcification of the carotid artery in a 3,000 year old Egyptian mummy.
Heavy calcification of the coronary arteries in a 3,000 year old Egyptian mummy.
Heavy calcification of the iliofemoral arteries showing peripheral artery disease (PAD) in a 3,000 year old Egyptian mummy.

A U.S.-Egyptian research team has uncovered the earliest documented case of coronary atherosclerosis in a princess who died in her early 40s and lived between 1580 and 1550 B.C.

The U.S. Food and Drug Administration (FDA) this week released its February list of device and technology premarket approvals (PMA), product development protocols (PDP), supplement and notice decisions.

To review the listing, visit: www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/ucm250089.htm

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now